MicroRNA‐19a regulates proliferation and apoptosis of castration‐resistant prostate cancer cells by targeting BTG1

Abstract

a b s t r a c tMicroRNAs (miRNAs) play a significant role in tumor development. Recent studies indicate that miRNAs are implicated in prostate cancer (PCa). In this study, we found that miR-19a expression was significantly increased in castration-resistant prostate cancer (CRPC) tissues compared with androgen-dependent prostate cancer (ADPC) tissues. We found that inhibiting the overexpression of miR-19a in CRPC cells suppressed proliferation and increased apoptosis. Additionally, we found that miR-19a repressed BTG1 expression by binding to its 3 0 -untranslated region. The overexpression of BTG1 in CRPC cells significantly suppressed proliferation and increased apoptosis. We conclude that miR-19a regulates proliferation and apoptosis of CRPC cells by directly targeting the tumor suppressor gene BTG1.

The emerging role of miR‐19 in glioma

“…41,42 MiR-19 promotes glioma cell proliferation that might be through inhibition on p53. MiR-19 also has been reported to promote tumour cell proliferation in other tumours such as pancreatic cancer, castration-resistant prostate cancer 43,44 and suppress tumour growth in lung cancer 45 as well.…”

MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity

“…Although differential expression of certain miRNAs between androgen-dependent prostate cancer (ADPC) and castration-resistant prostate cancer (CRPC) clinical samples has been reported, each of those studies was performed on only a few CRPC clinical samples. The cellular functions of these differentially expressed miRNAs identified in the clinical samples were also only investigated generally for PCa cell growth instead of the development of castration resistance [14][15][16]. We aimed to identify novel miRNAs associated with castration resistance in PCa and to investigate the downstream pathways and molecular mechanisms.…”

Mast cells influence neoangiogenesis in prostatic cancer independently of ERG status

“…In mice, adding MCs to injected PC cells increased the metastasis formation rate from 20 to 70% of cases. Similarly to in vitro studies, MC supplemented cases showed reduced AR and increased MMP9 expression [23].…”

“…Lu et al [23] found that in vitro antiandrogenic agents recruit increased numbers of mast cells. They found higher numbers of mast cells in vivo in PC than in adjacent non-neoplastic prostate as well as increased ability to recruit mast cells in vitro of prostate cancer cell lines compared to non-neoplastic prostate cell lines.…”